本研究针对急性髓系白血病(AML)和骨髓增生异常综合征(MDS)患者异基因造血干细胞移植(allo-HSCT)后复发率高的临床难题，通过系统评价和Meta分析9项比较性研究（含2项RCT），证实地西他滨(DAC)联合预处理方案可显著提升总生存期(HR 0.61)、降低复发风险(HR 0.58)且不 ...

本研究针对骨髓增生异常肿瘤/综合征（MDS）预后评估的临床需求，开展了一项关于淋巴细胞/单核细胞比值（L/M Ratio）预后 ...

Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, ...

Tuspetinib selected for a prestigious national clinical research program for ability to target broad spectrum of AML and MDS populations Trials to test tuspetinib in targeted drug combinations for ...

Researchers sought to determine whether combining enasidenib with venetoclax would be effective in patients with IDH2-mutated ...

SAN DIEGO and TORONTO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly ...

PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting LYT-200 is generally safe and well-tolerated as a single agent ...

The rate of relapse among patients with TP53-mutated myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) was similar among those who underwent allogeneic hematopoietic stem cell transplant ...

A rare mutation on the BCL6-corepressor gene correlated with worse overall survival in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However, allogenic stem cell ...